On October 11, according to Gan Li Pharmaceutical, the company's self-developed and produced glycine insulin injections officially obtained marketing approval from the British Medicines and Health Products Administration to treat diabetes in adults, adolescents, and children aged 2 and above.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.